Combination of valsartan, amlodipine and hydrochlorothiazide (Exforge HCT) approved in the EU for hypertension
Source: PharmaLive
Area: News
According to PharmaLive, the European Commission has granted marketing authorisation to Novartis for Exforge HCT®, a once-daily combination tablet containing valsartan, amlodipine, and hydrochlorothiazide (HCT) for hypertension.
nbsp;
Exforge HCT is indicated for substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of valsartan, amlodipine and HCT, taken either as three single-component formulations or as a dual-component and a single-component formulation.
nbsp;
Approval was supported by the results of a double-blind Phase III study (230211) comparing the efficacy and safety of triple therapy (valsartan, amlodipine and HCT) with the various dual combinations of its components (valsartan/HCT, amlod...
Calcium booster pills 'raise risk of heart attack and could do more harm than good'
Researchers claim the safety of the tablets is 'coming under increasing scrutiny' as they could be doing more harm than good. (Source: the Mail online | Health)
